US FDA Approval Climate: What Do The Oral Testosterone Reviews Tell Us?
Executive Summary
Second go-round for oral testosterone could have marked new boundary on how far FDA is willing to go in approving new entrants to a market with widespread historic off-label use and CV risks.
You may also be interested in...
Surprise Approval For Clarus' Oral Testosterone Includes Black Box, No REMS
Jatenzo clears US FDA 15 months after second negative advisory committee review.
Oral Testosterones Might Use REMS, CV Post-Market Study To Win Approval
US FDA advisory committee worries about off-label use of Lipocine's Tlando and Clarus' Jatenzo.
Jatenzo v. Tlando: Similar Issues Did Not Lead To Similar Votes
Two oral testosterone therapies solicited similar concerns, but sometimes different votes from advisory committee members on recommending approval.